Steinn Jonsson
University of Iceland
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Steinn Jonsson.
Nature | 2008
Thorgeir E. Thorgeirsson; Frank Geller; Patrick Sulem; Thorunn Rafnar; Anna Wiste; Kristinn P. Magnusson; Andrei Manolescu; Gudmar Thorleifsson; Hreinn Stefansson; Andres Ingason; Simon N. Stacey; Jon Thor Bergthorsson; Steinunn Thorlacius; Julius Gudmundsson; Thorlakur Jonsson; Margret Jakobsdottir; Jona Saemundsdottir; Olof Olafsdottir; Larus J. Gudmundsson; Gyda Bjornsdottir; Kristleifur Kristjansson; Halla Skuladottir; Helgi J. Ísaksson; Tomas Gudbjartsson; Gregory T. Jones; Thomas Mueller; Anders Gottsäter; Andrea Flex; Katja K. Aben; Femmie de Vegt
Smoking is a leading cause of preventable death, causing about 5 million premature deaths worldwide each year. Evidence for genetic influence on smoking behaviour and nicotine dependence (ND) has prompted a search for susceptibility genes. Furthermore, assessing the impact of sequence variants on smoking-related diseases is important to public health. Smoking is the major risk factor for lung cancer (LC) and is one of the main risk factors for peripheral arterial disease (PAD). Here we identify a common variant in the nicotinic acetylcholine receptor gene cluster on chromosome 15q24 with an effect on smoking quantity, ND and the risk of two smoking-related diseases in populations of European descent. The variant has an effect on the number of cigarettes smoked per day in our sample of smokers. The same variant was associated with ND in a previous genome-wide association study that used low-quantity smokers as controls, and with a similar approach we observe a highly significant association with ND. A comparison of cases of LC and PAD with population controls each showed that the variant confers risk of LC and PAD. The findings provide a case study of a gene–environment interaction, highlighting the role of nicotine addiction in the pathology of other serious diseases.
Nature Genetics | 2009
Thorunn Rafnar; Patrick Sulem; Simon N. Stacey; Frank Geller; Julius Gudmundsson; Asgeir Sigurdsson; Margret Jakobsdottir; Hafdis T. Helgadottir; Steinunn Thorlacius; Katja K. Aben; Thorarinn Blondal; Thorgeir E. Thorgeirsson; Gudmar Thorleifsson; Kristleifur Kristjansson; Kristin Thorisdottir; Rafn Ragnarsson; Bardur Sigurgeirsson; Halla Skuladottir; Tomas Gudbjartsson; Helgi J. Ísaksson; Gudmundur V. Einarsson; Kristrun R. Benediktsdottir; Bjarni A. Agnarsson; Karl Olafsson; Anna Salvarsdottir; Hjordis Bjarnason; Margret Asgeirsdottir; Kari T. Kristinsson; Sigurborg Matthiasdottir; Steinunn G Sveinsdottir
The common sequence variants that have recently been associated with cancer risk are particular to a single cancer type or at most two. Following up on our genome-wide scan of basal cell carcinoma, we found that rs401681[C] on chromosome 5p15.33 satisfied our threshold for genome-wide significance (OR = 1.25, P = 3.7 × 10−12). We tested rs401681 for association with 16 additional cancer types in over 30,000 cancer cases and 45,000 controls and found association with lung cancer (OR = 1.15, P = 7.2 × 10−8) and urinary bladder, prostate and cervix cancer (ORs = 1.07−1.31, all P < 4 × 10−4). However, rs401681[C] seems to confer protection against cutaneous melanoma (OR = 0.88, P = 8.0 × 10−4). Notably, most of these cancer types have a strong environmental component to their risk. Investigation of the region led us to rs2736098[A], which showed stronger association with some cancer types. However, neither variant could fully account for the association of the other. rs2736098 corresponds to A305A in the telomerase reverse transcriptase (TERT) protein and rs401681 is in an intron of the CLPTM1L gene.
Scandinavian Journal of Infectious Diseases | 1998
Sigurdur Einarsson; Mar Kristjansson; Karl G. Kristinsson; Gudbrandur Kjartansson; Steinn Jonsson
The objective of this study was to investigate the observation that patients with pneumonia due to penicillin-non-susceptible pneumococci (PNSP) in many instances present with milder disease than patients with pneumonia caused by penicillin-susceptible pneumococci (PSP) and to compare the cost of treatment. The clinical data, APACHE II score and laboratory features of hospitalized adults with pneumonia caused by PNSP or PSP were compared, along with antibiotic and hospital costs. Each patient with PNSP pneumonia (n = 36) was matched to a control with PSP pneumonia of the same age and gender. There was no difference in smoking history, but PNSP pneumonia patients had received prior antibiotics more frequently (p < 0.007). The mean APACHE II score was not different, but when broken down into acute vs. chronic scores those with PSP pneumonia had a significantly higher acute score (p = 0.005). Bacteraemia was present in 9 of 31 (29%) patients with PSP compared to 2 of 25 (8%) with the PNSP pneumonia (p = 0.09). The majority of isolates in the PNSP group were of serotype 6B (minimum inhibitory concentration range 0.125-2.0 mg/l), whereas serotypes 7, 9, 14, 18 and 19 were noted among the 9 PSP isolates. Compared with the control group, patients with the PNSP strains had a significantly longer hospital stay, 26.8 vs. 11.5 days (p = 0.001) and higher average antibiotic cost,
PLOS ONE | 2009
Pierre P. Massion; Yong Zou; Hasmet Uner; Porntip Kiatsimkul; Holly J. Wolf; Anna E. Barón; Tim Byers; Steinn Jonsson; Stephen Lam; Fred R. Hirsch; York E. Miller; Wilbur A. Franklin; Marileila Varella-Garcia
736 vs.
Thorax | 2006
Gunnar Gudmundsson; Ólafur Árni Sveinsson; Helgi J. Ísaksson; Steinn Jonsson; Halla Frodadottir; Thor Aspelund
213 (p < 0.0001). In conclusion, pneumonia in adults caused by PNSP is associated with a milder clinical presentation than infection caused by PSP, suggesting either that resistance carries a price or that the serotypes of PNSP are less virulent. Pneumonia due to PNSP resulted in increased cost because of prolonged hospitalization and the use of more expensive antibiotics.
Cancer Research | 2011
Thorunn Rafnar; Patrick Sulem; Søren Besenbacher; Daniel F. Gudbjartsson; Carlo Zanon; Julius Gudmundsson; Simon N. Stacey; Jelena Kostic; Thorgeir E. Thorgeirsson; Gudmar Thorleifsson; Hjordis Bjarnason; Halla Skuladottir; Tomas Gudbjartsson; Helgi J. Ísaksson; Dolores Isla; Laura Murillo; María Dolores García-Prats; Angeles Panadero; Katja K. Aben; Sita H. Vermeulen; Henricus F. M. van der Heijden; William J. Feser; York E. Miller; Paul A. Bunn; Augustine Kong; Holly J. Wolf; Wilbur A. Franklin; Jose I. Mayordomo; Lambertus A. Kiemeney; Steinn Jonsson
Lung carcinoma development is accompanied by field changes that may have diagnostic significance. We have previously shown the importance of chromosomal aneusomy in lung cancer progression. Here, we tested whether genomic gains in six specific loci, TP63 on 3q28, EGFR on 7p12, MYC on 8q24, 5p15.2, and centromeric regions for chromosomes 3 (CEP3) and 6 (CEP6), may provide further value in the prediction of lung cancer. Bronchial biopsy specimens were obtained by LIFE bronchoscopy from 70 subjects (27 with prevalent lung cancers and 43 individuals without lung cancer). Twenty six biopsies were read as moderate dysplasia, 21 as severe dysplasia and 23 as carcinoma in situ (CIS). Four-micron paraffin sections were submitted to a 4-target FISH assay (LAVysion, Abbott Molecular) and reprobed for TP63 and CEP 3 sequences. Spot counts were obtained in 30–50 nuclei per specimen for each probe. Increased gene copy number in 4 of the 6 probes was associated with increased risk of being diagnosed with lung cancer both in unadjusted analyses (odds ratio = 11, p<0.05) and adjusted for histology grade (odds ratio = 17, p<0.05). The most informative 4 probes were TP63, MYC, CEP3 and CEP6. The combination of these 4 probes offered a sensitivity of 82% for lung cancer and a specificity of 58%. These results indicate that specific cytogenetic alterations present in preinvasive lung lesions are closely associated with the diagnosis of lung cancer and may therefore have value in assessing lung cancer risk.
Journal of Thoracic Oncology | 2012
Hunbogi Thorsteinsson; Ásgeir Alexandersson; Gudrun Nina Oskarsdottir; Skúladóttir R; Helgi J. Ísaksson; Steinn Jonsson; Tomas Gudbjartsson
Background: Cryptogenic organising pneumonia (COP) has also been called idiopathic bronchiolitis obliterans organising pneumonia. In secondary organising pneumonia (SOP) the causes can be identified or it occurs in a characteristic clinical context. The aim of this study was to determine the incidence and epidemiological features of COP and SOP nationwide in Iceland over an extended period. Methods: A retrospective study of organising pneumonia (OP) in Iceland over 20 years was conducted and the epidemiology and survival were studied. All pathological reports of patients diagnosed with or suspected of having COP or SOP in the period 1984–2003 were identified and the pathology samples were re-evaluated using strict diagnostic criteria. Results: After re-evaluation, 104 patients fulfilled the diagnostic criteria for OP (58 COP and 46 SOP). The mean annual incidence of OP was 1.97/100 000 population (1.10/100 000 for COP and 0.87/100 000 for SOP). The mean age at diagnosis was 67 years with a wide age range. The most common causes of death were lung diseases other than OP, and only one patient died from OP. Patients with OP had a lower rate of survival than the general population, but there was no statistical difference between COP and SOP. Conclusions: The incidence of OP is higher than previously reported, suggesting that OP needs to be considered as a diagnosis more often than has been done in the past.
Molecular Psychiatry | 2016
Thorgeir E. Thorgeirsson; Stacy Steinberg; G. W. Reginsson; Gyda Bjornsdottir; Thorunn Rafnar; Ingileif Jonsdottir; Anna Helgadottir; Solveig Gretarsdottir; Hafdis T. Helgadottir; Steinn Jonsson; Stefan E. Matthiasson; Thorarinn Gislason; Thorarinn Tyrfingsson; Tomas Gudbjartsson; Helgi J. Ísaksson; H. Hardardottir; A. Sigvaldason; Lambertus A. Kiemeney; Aage Haugen; Shanbeh Zienolddiny; Holly J. Wolf; Wilbur A. Franklin; Angeles Panadero; Jose I. Mayordomo; Ian P. Hall; Eva Rönmark; Bo Lundbäck; Asger Dirksen; Haseem Ashraf; Jesper Holst Pedersen
Genome-wide association studies (GWAS) have identified 3 genomic regions, at 15q24-25.1, 5p15.33, and 6p21.33, which associate with the risk of lung cancer. Large meta-analyses of GWA data have failed to find additional associations of genome-wide significance. In this study, we sought to confirm 7 variants with suggestive association to lung cancer (P < 10(-5)) in a recently published meta-analysis. In a GWA dataset of 1,447 lung cancer cases and 36,256 controls in Iceland, 3 correlated variants on 15q15.2 (rs504417, rs11853991, and rs748404) showed a significant association with lung cancer, whereas rs4254535 on 2p14, rs1530057 on 3p24.1, rs6438347 on 3q13.31, and rs1926203 on 10q23.31 did not. The most significant variant, rs748404, was genotyped in an additional 1,299 lung cancer cases and 4,102 controls from the Netherlands, Spain, and the United States and the results combined with published GWAS data. In this analysis, the T allele of rs748404 reached genome-wide significance (OR = 1.15, P = 1.1 × 10(-9)). Another variant at the same locus, rs12050604, showed association with lung cancer (OR = 1.09, 3.6 × 10(-6)) and remained significant after adjustment for rs748404 and vice versa. rs748404 is located 140 kb centromeric of the TP53BP1 gene that has been implicated in lung cancer risk. Two fully correlated, nonsynonymous coding variants in TP53BP1, rs2602141 (Q1136K) and rs560191 (E353D) showed association with lung cancer in our sample set; however, this association did not remain significant after adjustment for rs748404. Our data show that 1 or more lung cancer risk variants of genome-wide significance and distinct from the coding variants in TP53BP1 are located at 15q15.2.
Journal of the National Cancer Institute | 2018
Thorunn Rafnar; Gudbjorg R Sigurjonsdottir; Simon N. Stacey; Gisli H. Halldorsson; Patrick Sulem; Luba M. Pardo; Hannes Helgason; Stefan T Sigurdsson; Thorkell Gudjonsson; Laufey Tryggvadottir; Gudridur Olafsdottir; Jon G. Jonasson; Kristin Alexiusdottir; Asgeir Sigurdsson; Julius Gudmundsson; Jona Saemundsdottir; Jon K. Sigurdsson; Hrefna Johannsdottir; André G. Uitterlinden; Sita H. Vermeulen; Tessel E. Galesloot; Dawn C. Allain; Martin Lacko; Bardur Sigurgeirsson; Kristin Thorisdottir; Oskar Johannsson; Fridbjorn Sigurdsson; Gunnar B Ragnarsson; Helgi J. Ísaksson; Hronn Hardardottir
Background: The proportion of patients with non–small-cell lung cancer (NSCLC) who undergo surgery with curative intent is one measure of effectiveness in treating lung cancer. To the best of our knowledge, surgical resection rate (SRR) for a whole nation has never been reported before. We studied the SRR and surgical outcome of NSCLC patients in Iceland during a recent 15-year period. Methods: This was a retrospective study of all pulmonary resections performed with curative intent for NSCLC in Iceland from 1994 to 2008. Information was retrieved from medical records and from the Icelandic Cancer Registry. Patient demographics, postoperative tumor, node, metastasis stage, overall survival, and complication rates were compared over three 5-year periods. Results: Of 1530 confirmed cases of NSCLC, 404 were resected, giving an SRR of 26.4%, which did not change significantly during the study period. Minor and major complication rates were 37.4% and 8.7%, respectively. Operative mortality rates were 0.7% for lobectomy, 3.3% for pneumonectomy, and 0% for lesser resection. Five-year survival after all procedures was 40.7% and improved from the first to the last 5-year period (34.8% versus 43.8%, p = 0.04). Five-year survival for stages I and II together was 46.8%, with no significant change in stage distribution between periods. Five-year survival after pneumonectomy was 22.0%, which was significantly lower than for lobectomy (44.6%) and lesser resection (40.7%) (p < 0.005). Unoperated patients had a 5-year survival of 4.8%, as compared to 12.4% for all the NSCLC patients together. Conclusion: Compared with most other published studies, the SRR of NSCLC in Iceland is high. Short-term outcome is good, with a low rate of major complications and an operative mortality of only 1.0%. Five-year survival improved significantly over the study period.
Apmis | 2016
Gudrun Nina Oskarsdottir; Johannes Bjornsson; Steinn Jonsson; Helgi J. Ísaksson; Tomas Gudbjartsson
Using Icelandic whole-genome sequence data and an imputation approach we searched for rare sequence variants in CHRNA4 and tested them for association with nicotine dependence. We show that carriers of a rare missense variant (allele frequency=0.24%) within CHRNA4, encoding an R336C substitution, have greater risk of nicotine addiction than non-carriers as assessed by the Fagerstrom Test for Nicotine Dependence (P=1.2 × 10−4). The variant also confers risk of several serious smoking-related diseases previously shown to be associated with the D398N substitution in CHRNA5. We observed odds ratios (ORs) of 1.7–2.3 for lung cancer (LC; P=4.0 × 10−4), chronic obstructive pulmonary disease (COPD; P=9.3 × 10−4), peripheral artery disease (PAD; P=0.090) and abdominal aortic aneurysms (AAAs; P=0.12), and the variant associates strongly with the early-onset forms of LC (OR=4.49, P=2.2 × 10−4), COPD (OR=3.22, P=2.9 × 10−4), PAD (OR=3.47, P=9.2 × 10−3) and AAA (OR=6.44, P=6.3 × 10−3). Joint analysis of the four smoking-related diseases reveals significant association (P=6.8 × 10−5), particularly for early-onset cases (P=2.1 × 10−7). Our results are in agreement with functional studies showing that the human α4β2 isoform of the channel containing R336C has less sensitivity for its agonists than the wild-type form following nicotine incubation.